Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Antengene to Start Trial of PD-L1/4-1BB Bispecific in Solid Tumors and NHL

publication date: Jul 22, 2021

Shanghai's Antengene was approved to start an Australian Phase I trial of its PD-L1/4-1BB bispecific antibody. The trial will evaluate the safety and tolerability of ATG-101 as a single agent in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Antengene, which developed ATG-101 in-house and continues to hold global rights to the candidate, plans to file INDs for China and US trials of ATG-101 later this year. More details....

Stock Symbol: (HK: 6996)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021